{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:53:59Z","timestamp":1789588439669,"version":"build-2803163510"},"reference-count":45,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2019.4801","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T11:27:23Z","timestamp":1557833243000},"source":"Crossref","is-referenced-by-count":14,"title":["PF\u2011114, a novel selective inhibitor of BCR\u2011ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells"],"prefix":"10.3892","author":[{"given":"Ekaterina","family":"Ivanova","sequence":"first","affiliation":[{"name":"Blokhin National Medical Center of Oncology, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Tatarskiy","sequence":"additional","affiliation":[{"name":"Blokhin National Medical Center of Oncology, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Yastrebova","sequence":"additional","affiliation":[{"name":"Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina","family":"Khamidullina","sequence":"additional","affiliation":[{"name":"Moscow State University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Shunaev","sequence":"additional","affiliation":[{"name":"Blokhin National Medical Center of Oncology, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kalinina","sequence":"additional","affiliation":[{"name":"Blokhin National Medical Center of Oncology, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Zeifman","sequence":"additional","affiliation":[{"name":"Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, and FusionPharma, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Novikov","sequence":"additional","affiliation":[{"name":"Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, and FusionPharma, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Dutikova","sequence":"additional","affiliation":[{"name":"Federal Institute of Industrial Property, 125993 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghermes","family":"Chilov","sequence":"additional","affiliation":[{"name":"Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, and FusionPharma, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shtil","sequence":"additional","affiliation":[{"name":"Blokhin National Medical Center of Oncology, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"key20200713185911_b1-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s004320050228","article-title":"Chronic myelogenous leukemia: Molecular and cellular aspects","volume":"124","author":"Pasternak","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20200713185911_b2-ijo-55-01-0289","first-page":"129","article-title":"Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition","volume":"62","author":"Lin","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"key20200713185911_b3-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"IRIS Investigators: Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200713185911_b4-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"key20200713185911_b5-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"PACE Investigators: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"key20200713185911_b6-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: A review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"key20200713185911_b7-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200713185911_b8-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"key":"key20200713185911_b9-ijo-55-01-0289","unstructured":"ChilovGGTitovIYProtein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical compositionPatentRU2477723 (C2)Filed July 10, 2017; issued August 31, 2017"},{"key":"key20200713185911_b10-ijo-55-01-0289","unstructured":"Cellosaurus - a knowledge resource on cell linesVersion 29. https:\/\/web.expasy.org\/cellosaurus\/CVCL_0002"},{"key":"key20200713185911_b11-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/icb.2013.64","article-title":"The adaptor protein Crk in immune response","volume":"92","author":"Liu","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"key20200713185911_b12-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejmech.2016.01.050","article-title":"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties","volume":"112","author":"Shchekotikhin","year":"2016","journal-title":"Eur J Med Chem"},{"key":"key20200713185911_b13-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"25","DOI":"10.15171\/bi.2015.01","article-title":"An update to DNA ladder assay for apoptosis detection","volume":"5","author":"Rahbar Saadat","year":"2015","journal-title":"Bioimpacts"},{"key":"key20200713185911_b14-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20200713185911_b15-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"key20200713185911_b16-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-3-319-91439-8_5","article-title":"Ponatinib: A third-generation inhibitor for the treatment of CML","volume":"212","author":"Wehrle","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"key20200713185911_b17-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","article-title":"A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors","volume":"7","author":"Zulbaran-Rojas","year":"2018","journal-title":"Cancer Med"},{"key":"key20200713185911_b18-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nprot.2015.007","article-title":"Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines","volume":"10","author":"Aspinall-O'Dea","year":"2015","journal-title":"Nat Protoc"},{"key":"key20200713185911_b19-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000453133","article-title":"The PI3K pathway: Background and treatment approaches","volume":"11","author":"Lux","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"key20200713185911_b20-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.02.037","article-title":"PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials","volume":"175","author":"Dey","year":"2017","journal-title":"Pharmacol Ther"},{"key":"key20200713185911_b21-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tips.2017.02.001","article-title":"A new view of pathway-driven drug resistance in tumor proliferation","volume":"38","author":"Nussinov","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"key20200713185911_b22-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.bbamcr.2015.03.012","article-title":"Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment","volume":"1853","author":"Correia","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"key20200713185911_b23-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s10495-010-0503-y","article-title":"Phosphatidylserine targeting for diagnosis and treatment of human diseases","volume":"15","author":"Schutters","year":"2010","journal-title":"Apoptosis"},{"key":"key20200713185911_b24-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1478-811X-8-31","article-title":"PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration","volume":"8","author":"Chaitanya","year":"2010","journal-title":"Cell Commun Signal"},{"key":"key20200713185911_b25-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"'Do We Know Jack' about JAK? A closer look at JAK\/STAT signaling pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front Oncol"},{"key":"key20200713185911_b26-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.3109\/10428194.2015.1007507","article-title":"Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6\/Janus activated kinase\/signal transducer and activator of transcription 3 signaling cohort","volume":"56","author":"Ma","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key20200713185911_b27-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"108880","DOI":"10.18632\/oncotarget.22353","article-title":"Matrine inhibits BCR\/ABL mediated ERK\/MAPK pathway in human leukemia cells","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713185911_b28-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-17-1733","article-title":"Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"key":"key20200713185911_b29-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/leu.2016.53","article-title":"Aberrant activation of CaMKII\u03b3 accelerates chronic myeloid leukemia blast crisis","volume":"30","author":"Gu","year":"2016","journal-title":"Leukemia"},{"key":"key20200713185911_b30-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"key":"key20200713185911_b31-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1186\/1471-2407-14-866","article-title":"Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia","volume":"14","author":"Mencalha","year":"2014","journal-title":"BMC Cancer"},{"key":"key20200713185911_b32-ijo-55-01-0289","doi-asserted-by":"crossref","first-page":"18638","DOI":"10.18632\/oncotarget.7888","article-title":"Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"key20200713185911_b33-ijo-55-01-0289","first-page":"7","article-title":"Roles of STAT3 in leukemia (Review)","volume":"53","author":"Shi","year":"2018","journal-title":"Int J Oncol"},{"key":"key20200713185911_b34-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08977194.2018.1473393","article-title":"STAT3: A multifaceted oncoprotein","volume":"36","author":"Guanizo","year":"2018","journal-title":"Growth Factors"},{"key":"key20200713185911_b35-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"E1591","DOI":"10.3390\/ijms19061591","article-title":"Structural biology of STAT3 and its implications for anticancer therapies development","volume":"19","author":"Sgrignani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20200713185911_b36-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.7314\/APJCP.2014.15.11.4555","article-title":"Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells","volume":"15","author":"Al-Jamal","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20200713185911_b37-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/leu.2017.14","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"31","author":"Eiring","year":"2017","journal-title":"Leukemia"},{"key":"key20200713185911_b38-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"key":"key20200713185911_b39-ijo-55-01-0289","unstructured":"SinghHWilliamsRTGuyKRMethods and compositions for the treatment of Bcr-Abl positive lymphoblastic leukemiasPatentUS20150133462 A1Filed May 23, 2013; issued May 14, 2015"},{"key":"key20200713185911_b40-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-17-0009","article-title":"Cotargeting of MEK and PDGFR\/STAT3 pathways to treat pancreatic ductal adenocarcinoma","volume":"16","author":"Sahu","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"key20200713185911_b41-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bpa.12254","article-title":"STAT3 serine 727 phosphorylation: A relevant target to radiosen-sitize human glioblastoma","volume":"26","author":"Ou\u00e9draogo","year":"2016","journal-title":"Brain Pathol"},{"key":"key20200713185911_b42-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7150\/ijbs.14878","article-title":"In vitro antileukemia activity of ZSTK474 on K562 and multidrug resistant K562\/A02 cells","volume":"12","author":"Zhou","year":"2016","journal-title":"Int J Biol Sci"},{"key":"key20200713185911_b43-ijo-55-01-0289","doi-asserted-by":"crossref","first-page":"36","DOI":"10.18632\/genesandcancer.93","article-title":"BCR: A new target in resistance mediated by BCR\/ABL-315I?","volume":"7","author":"Haberbosch","year":"2016","journal-title":"Genes Cancer"},{"key":"key20200713185911_b44-ijo-55-01-0289","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/leu.2009.69","article-title":"The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL","volume":"23","author":"Mian","year":"2009","journal-title":"Leukemia"},{"key":"key20200713185911_b45-ijo-55-01-0289","unstructured":"NIHU.S. National Library of Medicine. ClinicalTrials. Study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adults with Ph+ chronic myeloid leukemia, which is resistant to the 2-nd generation Bcr-Abl inhibitors or Has T315I mutation in the BCR-ABL geneNCT02885766https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02885766"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T19:35:54Z","timestamp":1607801754000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2019.4801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":45,"URL":"https:\/\/doi.org\/10.3892\/ijo.2019.4801","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]}}}